Corvus Pharmaceuticals, Inc.
CRVS
$3.22
-$0.02-0.62%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -82.07% | -570.28% | 34.46% | 27.59% | 32.22% |
| Total Depreciation and Amortization | -28.57% | -30.00% | -41.67% | -59.65% | -70.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 175.12% | 2,793.40% | -144.47% | -84.58% | -63.42% |
| Change in Net Operating Assets | -273.15% | 121.90% | -70.85% | 109.72% | 86.42% |
| Cash from Operations | -63.83% | -16.32% | -4.94% | 36.42% | 31.54% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -162.64% | -122.17% | -308.11% | -100.15% | 40.63% |
| Cash from Investing | -162.42% | -122.17% | -308.11% | -100.15% | 40.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -85.07% | 118.27% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -85.07% | 304.07% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 154.24% | -181.63% | 469.99% | -47.33% | 34.51% |